To ensure the quality and safety of medical services in primary healthcare institutions, China’s National Health Commission (NHC) and other relevant authorities issued a notice on 1 April 2026, outlining a three-year nationwide action.

Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Danaher on Thursday reported a 23 percent year-over-year increase in third quarter revenues, which included a rise of nearly 25 percent in life sciences revenues and of nearly 30 percent in diagnostics revenues.

BioMérieux reported on Thursday that its third quarter revenues grew 11 percent year over year, driven by growth across its application areas.

Cell fitness has been identified as a way of predicting health outcomes in COVID patients, according to a University of Queensland study.

Abbott reported Wednesday that its third quarter Diagnostics business revenues rose 48 percent year over year, mainly driven by sales in its Core Laboratory and Rapid Diagnostics businesses.

Roche said on Wednesday that its diagnostics division revenues grew 38 percent year over year, or 39 percent at constant exchange rates, in the first nine months of 2021, due to high demand for COVID-19 tests, recovery in the base business, and the launch of new diagnostic platforms.

October 19, 2021, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (“Mindray”) (300760.SZ) released the third quarter report: sale in the third quarter was 6.613 billion CNY, up 20.25% year on year.

Skin disease diagnostics company Castle Biosciences said on Tuesday that it has signed a definitive agreement to acquire Cernostics, a privately held firm that specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies.

The US Food and Drug Administration last week granted Emergency Use Authorization for Lighthouse Lab Services' CovidNow SARS-CoV-2 Assay.

On October 18, 2021, ACROBiosystems listed on Shenzhen Stock Exchange (SZSE) ChiNext. The issue price is RMB 112.5 per share, and the opening price is RMB 198 per share. The total amount of funds to be raised is 2.25 billion yuan.

Type 1 Diabetes Mellitus (T1DM) is an autoimmune disease that occurs due to destruction of the islets of Langerhans in the pancreas. These islets contain β cells and when destroyed, it reduces the body’s ability to produce insulin leading to hyperglycemia.